PF-06869206，≥98% (HPLC)

PF-06869206 has been used to selectively inhibit the activity of sodium-phosphate cotransporter 2a (NaPi2a).

PF-06869206 已被用于选择性抑制磷酸钠协同转运蛋白 2a (NaPi2a) 的活性。

 

PF-06869206 is a selective inhibitor against sodium-phosphate cotransporter 2A (NaPi-2a, NaPi-Iia, Na+/Pi cotransporter 2A, Na+-dependent phosphate cotransporter 2A).

PF-06869206 may be used to treat patients with mineral and hormonal derangements linked with increased cardiovascular risk in chronic kidney disease. This drug might also improve urinary phosphate excretion. PF-06869206 has an ability to decrease phosphate uptake in human embryonic kidney (HEK) cells transfected with mouse or rat renal sodium-dependent phosphate transporter genes (Npt2a).

 

PF-06869206 是一种选择性抑制剂，可抑制钠-磷酸协同转运蛋白 2A（NaPi-2a、NaPi-Iia、Na+/Pi 协同转运蛋白 2A、Na+ 依赖性磷酸协同转运蛋白 2A）。
PF-06869206 可用于治疗与慢性肾病心血管风险增加有关的矿物质和激素紊乱患者。 这种药物也可能改善尿磷酸盐的排泄。 PF-06869206 能够降低用小鼠或大鼠肾钠依赖性磷酸盐转运蛋白基因 (Npt2a) 转染的人胚胎肾 (HEK) 细胞中的磷酸盐摄取。

 

Sold for research purposes under agreement from Pfizer Inc

Pfizer is a registered trademark of Pfizer, Inc.